Cargando…

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma

Although osteosarcoma (OS) is a rare cancer, it is the most common primary malignant bone tumor in children and adolescents. BRCAness is a phenotypical trait in tumors with a defect in homologous recombination repair, resembling tumors with inactivation of BRCA1/2, rendering these tumors sensitive t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barenboim, Maxim, Kovac, Michal, Ameline, Baptiste, Jones, David T. W., Witt, Olaf, Bielack, Stefan, Burdach, Stefan, Baumhoer, Daniel, Nathrath, Michaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584788/ https://www.ncbi.nlm.nih.gov/pubmed/34762643 http://dx.doi.org/10.1371/journal.pcbi.1009562

Ejemplares similares

Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
por: Ameline, Baptiste, et al.
Publicado: (2020)

The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies
por: Kovac, Michal, et al.
Publicado: (2021)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

NTRK fusions in osteosarcoma are rare and non‐functional events
por: Ameline, Baptiste, et al.
Publicado: (2020)

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
por: Kovac, Michal, et al.
Publicado: (2015)

CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients
por: Baumhoer, Daniel, et al.
Publicado: (2011)

Solitary pulmonary metastases at first recurrence of osteosarcoma: Presentation, treatment, and survival of 219 patients of the Cooperative Osteosarcoma Study Group
por: Mettmann, Vanessa L., et al.
Publicado: (2023)

Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation
por: Poos, Kathrin, et al.
Publicado: (2014)

Methylation and copy number profiling: emerging tools to differentiate osteoblastoma from malignant mimics?
por: Ameline, Baptiste, et al.
Publicado: (2022)

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

How MicroRNA and Transcription Factor Co-regulatory Networks Affect Osteosarcoma Cell Proliferation
por: Poos, Kathrin, et al.
Publicado: (2013)

Genomic Heterogeneity of Osteosarcoma - Shift from Single Candidates to Functional Modules
por: Poos, Kathrin, et al.
Publicado: (2015)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

A complex pattern of chemokine receptor expression is seen in osteosarcoma
por: von Luettichau, Irene, et al.
Publicado: (2008)

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
por: Holme, Harriett, et al.
Publicado: (2018)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

New Small Molecules Targeting Apoptosis and Cell Viability in Osteosarcoma
por: Maugg, Doris, et al.
Publicado: (2015)

Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness
por: Darbeheshti, Farzaneh, et al.
Publicado: (2022)

Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma – reasons and consequences
por: Arabi, Leila, et al.
Publicado: (2014)

The long non-coding RNA PARTICLE is associated with WWOX and the absence of FRA16D breakage in osteosarcoma patients
por: O'Leary, Valerie Bríd, et al.
Publicado: (2017)

Review of mifamurtide in the treatment of patients with osteosarcoma
por: Kager, Leo, et al.
Publicado: (2010)

Advances in the management of osteosarcoma
por: Bielack, Stefan S., et al.
Publicado: (2016)

Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma
por: Strauss, Sandra J., et al.
Publicado: (2018)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients
por: Schuster, Anne J., et al.
Publicado: (2018)

Osteosarcoma of the Mandible in a Patient with Florid Cemento-Osseous Dysplasia and Li–Fraumeni Syndrome: A Rare Coincidence
por: Haefliger, Simon, et al.
Publicado: (2020)

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
por: Wysham, Weiya Z., et al.
Publicado: (2012)

BRCAness as a prognostic indicator in patients with early breast cancer
por: Liu, Lei, et al.
Publicado: (2020)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
por: Caeiro, Cláudia, et al.
Publicado: (2022)

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
por: Tutt, A
Publicado: (2018)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients
por: Hecker-Nolting, Stefanie, et al.
Publicado: (2021)

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
por: Li, Hongyi, et al.
Publicado: (2020)

Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
por: Evdokimova, Valentina, et al.
Publicado: (2022)

Metachronous Osteosarcoma, A Differential Diagnosis to be Considered in Children With Osteosarcoma: A Review of Literature and a Case From Our Center
por: Gotta, Jennifer, et al.
Publicado: (2023)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9dn2k3obv0mfemtsgol2m428lm